The pathogenesis of idiopathic pulmonary fibrosis (IPF) remains largely unknown. It is believed that IPF is mainly driven by activated alveolar epithelial cells that have a compromised migration capacity, and that also produce substances (such as connective tissue growth factor, CTGF) that contribute to fibroblast activation and matrix protein accumulation. Because the mechanisms regulating these processes are unclear, the aim of this study was to determine the role of rapamycin in regulating epithelial cell migration and CTGF expression. Transformed epithelial cell line A549 and normal human pulmonary alveolar or bronchial epithelial cells were cultured in regular medium or medium containing rapamycin. Real time reverse transcriptase polymerase chain reaction was employed to determine CTGF mRNA expression. Western blotting and an enzyme-linked immunosorbent assay were used for detecting CTGF protein. Wound healing and migration assays were used to determine the cell migration potential. Transforming growth factor (TGF)-β type I receptor (TβRI) inhibitor, SB431542 and phosphoinositide 3-kinase (PI3K) inhibitor, LY294002 were used to determine rapamycin’s mechanism of action. It was found that treatment of A549 and normal human alveolar or bronchial epithelial cells with rapamycin significantly promoted basal or TGF-β1 induced CTGF expression. LY294002, not SB431542 attenuated the promotional effect of rapamycin on CTGF expression. Cell mobility was not affected by rapamycin in wound healing and migration assays. These data suggest rapamycin has a profibrotic effect in vitro and underscore the potential of combined therapeutic approach with PI3K and mammalian target of rapamycin inhibitors for the treatment of animal or human lung fibrosis.
American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med2000; 161(2 Pt 1): 646–64.
2.
American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med2002; 165: 277–304.
3.
Fernandez PerezERDanielsCESchroederDRSt SauverJHartmanTEBartholmaiBJ. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest2010; 137: 129–37.
CowardWRSainiGJenkinsG. The pathogenesis of idiopathic pulmonary fibrosis. Ther Adv Respir Dis2010; 4: 367–88.
6.
KottmannRMHoganCMPhippsRPSimePJ. Determinants of initiation and progression of idiopathic pulmonary fibrosis. Respirology2009; 14: 917–33.
7.
HardieWDHagoodJSDaveVPerlAKWhitsettJAKorfhagenTR. Signaling pathways in the epithelial origins of pulmonary fibrosis. Cell Cycle2010; 9: 2769–76.
8.
CrosbyLMWatersCM. Epithelial repair mechanisms in the lung. Am J Physiol Lung Cell Mol Physiol2010; 298: L715–31.
9.
LeeCGChoSJKangMJChapovalSPLeePJNoblePW. Early growth response gene 1-mediated apoptosis is essential for transforming growth factor beta1-induced pulmonary fibrosis. J Exp Med2004; 200: 377–89.
10.
DrakopanagiotakisFXifteriAPolychronopoulosVBourosD. Apoptosis in lung injury and fibrosis. Eur Respir J2008; 32: 1631–8.
11.
VezinaCKudelskiASehgalSN. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo)1975; 28: 721–6.
12.
WullschlegerSLoewithRHallMN. TOR signaling in growth and metabolism. Cell2006; 124: 471–84.
13.
DanceyJ. mTOR signaling and drug development in cancer. Nat Rev Clin Oncol2010; 7: 209–19.
14.
BridleKRPopaCMorganMLSobbeALCloustonADFletcherLM. Rapamycin inhibits hepatic fibrosis in rats by attenuating multiple profibrogenic pathways. Liver Transpl2009; 15: 1315–24.
OsmanBDollerAAkool elSHoldenerMHintermannEPfeilschifterJ. Rapamycin induces the TGFbeta1/Smad signaling cascade in renal mesangial cells upstream of mTOR. Cell Signal2009; 21: 1806–17.
21.
CarracedoAMaLTeruya-FeldsteinJRojoFSalmenaLAlimontiA. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest2008; 118: 3065–74.
22.
SehgalSN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc2003; 35: 7S–14S.
23.
MartelRRKliciusJGaletS. Inhibition of the immune response by rapamycin, a new antifungal antibiotic. Can J Physiol Pharmacol1977; 55: 48–51.
24.
AbrahamRTGibbonsJJ. The mammalian target of rapamycin signaling pathway: twists and turns in the road to cancer therapy. Clin Cancer Res2007; 13: 3109–14.
25.
HwangMPerezCAMorettiLLuB. The mTOR signaling network: insights from its role during embryonic development. Curr Med Chem2008; 15: 1192–208.
26.
BrigstockDR. Connective tissue growth factor (CCN2, CTGF) and organ fibrosis: lessons from transgenic animals. J Cell Commun Signal2010; 4: 1–4.
27.
LeaskAHolmesAAbrahamDJ. Connective tissue growth factor: a new and important player in the pathogenesis of fibrosis. Curr Rheumatol Rep2002; 4: 136–42.
28.
SonnylalSShi-WenXLeoniPNaffKVan PeltCSNakamuraH. Selective expression of connective tissue growth factor in fibroblasts in vivo promotes systemic tissue fibrosis. Arthritis Rheum2010; 62: 1523–32.
29.
KodamaTTakeharaTHikitaHShimizuSShigekawaMTsunematsuH. Increases in p53 expression induce CTGF synthesis by mouse and human hepatocytes and result in liver fibrosis in mice. J Clin Invest2011; 121: 3343–56.
30.
DendoovenAGerritsenKGNguyenTQKokRJGoldschmedingR. Connective tissue growth factor (CTGF/CCN2) ELISA: a novel tool for monitoring fibrosis. Biomarkers2011; 16: 289–301.
31.
O'ConnellSSlatteryCRyanMPMcMorrowT. Sirolimus enhances cyclosporine a-induced cytotoxicity in human renal glomerular mesangial cells. J Transplant2012; 2012: 980910–980910.
32.
ShihabFSBennettWMYiHAndohTF. Effect of cyclosporine and sirolimus on the expression of connective tissue growth factor in rat experimental chronic nephrotoxicity. Am J Nephrol2006; 26: 400–7.
33.
LiuMZhangWGuMYinCZhangWYLvQ. Protective effects of sirolimus by attenuating connective tissue growth factor expression in human chronic allograft nephropathy. Transplant Proc2007; 39: 1410–5.
34.
VivancoISawyersCL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer2002; 2: 489–501.
35.
EngelmanJALuoJCantleyLC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet2006; 7: 606–19.
36.
StephensLAndersonKStokoeDErdjument-BromageHPainterGFHolmesAB. Protein kinase B kinases that mediate phosphatidylinositol 3,4,5-trisphosphate-dependent activation of protein kinase B. Science1998; 279: 710–4.
FanQWKnightZAGoldenbergDDYuWMostovKEStokoeD. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell2006; 9: 341–9.
39.
SunSYRosenbergLMWangXZhouZYuePFuH. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res2005; 65: 7052–8.
40.
O'ReillyKERojoFSheQBSolitDMillsGBSmithD. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res2006; 66: 1500–8.
41.
RobertsPJUsaryJEDarrDBDillonPMPfefferleADWhittleMC. Combined PI3K/mTOR and MEK inhibition provides broad antitumor activity in faithful murine cancer models. Clin Cancer Res2012; 18: 5290–303.
42.
LorenzenJMSchonenbergerEHaferCHoeperMKielsteinJT. Failed rescue therapy with rapamycin after paraquat intoxication. Clin Toxicol (Phila)2010; 48: 84–6.
